MA32967B1 - Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile - Google Patents

Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile

Info

Publication number
MA32967B1
MA32967B1 MA34016A MA34016A MA32967B1 MA 32967 B1 MA32967 B1 MA 32967B1 MA 34016 A MA34016 A MA 34016A MA 34016 A MA34016 A MA 34016A MA 32967 B1 MA32967 B1 MA 32967B1
Authority
MA
Morocco
Prior art keywords
sgc
treatment
combination
pde5 inhibitors
erectile dysfunction
Prior art date
Application number
MA34016A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Sandner
Johannes-Peter Stasch
Michael-Friedrich Böttcher
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA32967B1 publication Critical patent/MA32967B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne la cyclase guanylate soluble (sGC) et des phosphodiestérases (PDE), ainsi que la pharmacologie des stimulateurs sGC, des activateurs sGC et des inhibiteurs PDE. Plus particulièrement, l'invention concerne l'utilisation de stimulateurs sGC et d'activateurs sGC en combinaison avec des inhibiteurs PDE5, dans la préparation de médicaments destinés au traitement du dysfonctionnement érectile masculin (MED), et en particulier au traitement du MED pour des patients difficiles à traiter et des patients ne réagissant pas, ou pas totalement, aux inhibiteurs de PDE5.
MA34016A 2009-01-17 2010-01-07 Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile MA32967B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09000619 2009-01-17
EP09002177 2009-02-17
PCT/EP2010/000029 WO2010081647A2 (fr) 2009-01-17 2010-01-07 Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile

Publications (1)

Publication Number Publication Date
MA32967B1 true MA32967B1 (fr) 2012-01-02

Family

ID=42153923

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34016A MA32967B1 (fr) 2009-01-17 2010-01-07 Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile

Country Status (20)

Country Link
US (2) US20120022028A1 (fr)
EP (1) EP2387404B1 (fr)
JP (1) JP5780430B2 (fr)
KR (1) KR20110117655A (fr)
CN (1) CN102316870A (fr)
AU (1) AU2010205931A1 (fr)
BR (1) BRPI1006869A2 (fr)
CA (1) CA2749730C (fr)
CL (1) CL2011001712A1 (fr)
EA (1) EA201170942A1 (fr)
ES (1) ES2493718T3 (fr)
IL (1) IL213857A0 (fr)
MA (1) MA32967B1 (fr)
MX (1) MX2011007515A (fr)
SG (1) SG172841A1 (fr)
SV (1) SV2011003973A (fr)
TN (1) TN2011000349A1 (fr)
TW (1) TW201036971A (fr)
WO (1) WO2010081647A2 (fr)
ZA (1) ZA201105085B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095553A1 (fr) * 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Stimulateurs de sgc ou activateurs de sgc en combinaison avec des inhibiteurs de pde5 pour le traitement du dysfonctionnement érectile
CN103038232B (zh) 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
EP2585055A1 (fr) * 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
US8815857B2 (en) 2011-08-12 2014-08-26 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
KR101960100B1 (ko) * 2011-12-08 2019-03-19 에스케이케미칼 주식회사 미로데나필 또는 이의 약학적으로 허용 가능한 염을 함유하는 구강 투여용 필름
NZ703989A (en) * 2012-09-07 2017-04-28 Boehringer Ingelheim Int Alkoxy pyrazoles as soluble guanylate cyclase activators
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
EP3082428A4 (fr) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
WO2016014463A1 (fr) 2014-07-22 2016-01-28 Boehringer Ingelheim International Gmbh Acides carboxyliques hétérocycliques en tant qu'activateurs de la guanylate cyclase soluble
SG11201802710YA (en) 2015-11-16 2018-06-28 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
CA3060525A1 (fr) 2017-05-22 2018-11-29 Topadur Pharma Ag Nouveaux activateurs de la guanylate cyclase solubles a double mode d'action, inhibiteurs de phosphodiesterase et leurs utilisations
EP3887376A1 (fr) 2018-11-28 2021-10-06 Topadur Pharma AG Nouveaux activateurs de la guanylate cyclase solubles à double mode d'action, inhibiteurs de phosphodiestérase et leurs utilisations
CN110305837A (zh) * 2019-06-05 2019-10-08 西北师范大学 磷酸二酯酶5活性抑制剂作为诱导斑马鱼卵母细胞成熟的催熟剂的应用
WO2021245192A1 (fr) 2020-06-04 2021-12-09 Topadur Pharma Ag Nouveaux activateurs de la guanylate cyclase soluble à double mode d'action et inhibiteurs de phosphodiestérase et leurs utilisations
CN117462685A (zh) * 2023-04-14 2024-01-30 北京悦康科创医药科技股份有限公司 Pde5抑制剂或其组合物在制备用于治疗泌尿系统疾病药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB371800A (en) 1929-10-21 1932-04-28 Willem Zaadnoordijk A process of filtering gases and fogs
GB369003A (en) 1931-03-25 1932-03-17 Richard Henry Sansome Improvements in fire extinguishing fluids
KR100720844B1 (ko) * 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 ｎ-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2008124505A2 (fr) * 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Modulateurs de la guanylate soluble (scg) pour le traitement de troubles liés aux lipides
AU2008250643A1 (en) * 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC stimulators, sGC activators and combinations for the treatment of urological disorders

Also Published As

Publication number Publication date
MX2011007515A (es) 2011-08-12
BRPI1006869A2 (pt) 2016-03-15
WO2010081647A3 (fr) 2010-10-21
CN102316870A (zh) 2012-01-11
US20120022028A1 (en) 2012-01-26
EP2387404B1 (fr) 2014-06-25
WO2010081647A2 (fr) 2010-07-22
ES2493718T3 (es) 2014-09-12
KR20110117655A (ko) 2011-10-27
CA2749730C (fr) 2017-02-14
CL2011001712A1 (es) 2012-04-09
SG172841A1 (en) 2011-08-29
TW201036971A (en) 2010-10-16
SV2011003973A (es) 2011-12-06
EA201170942A1 (ru) 2012-02-28
JP2012515176A (ja) 2012-07-05
JP5780430B2 (ja) 2015-09-16
AU2010205931A1 (en) 2011-07-28
TN2011000349A1 (en) 2013-03-27
EP2387404A2 (fr) 2011-11-23
IL213857A0 (en) 2011-07-31
ZA201105085B (en) 2012-09-26
CA2749730A1 (fr) 2010-07-22
US20140288079A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
TN2011000349A1 (en) Sgc stimulators of sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
EA201290702A1 (ru) СТИМУЛЯТОРЫ sGC ИЛИ АКТИВАТОРЫ sGC, ПРИМЕНЯЕМЫЕ ДЛЯ ЛЕЧЕНИЯ КИСТОЗНОГО ФИБРОЗА ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С ИНГИБИТОРАМИ PDE5
EP4275752A3 (fr) Traitement d'addiction et de troubles de contrôle des impulsions au moyen d'inhibiteurs de la pde7
MA34002B1 (fr) Thérapie antivirale
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
RU2009120992A (ru) Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
TW200510425A (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
MA32903B1 (fr) Inhibiteurs de proteine-kinases
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
MX2010004281A (es) Composiciones y metodos para el tratamiento de la retinopatia diabetica.
MA33768B1 (fr) Triazolopyridines
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA31335B1 (fr) Procédés de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MY144773A (en) 6-(heterocycle-susbtituted benzyl) -4-oxoquinoline compound and use of the same as hiv integrase inhibitor
WO2018089330A8 (fr) Stimulateurs de sgc
MX2007002689A (es) 7-azaindoles y su uso como agonistas de ppar.
TW200621236A (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases